安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Fact Sheet: The 340B Drug Pricing Program | AHA
Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients
- 340B Drug Pricing Program - Wikipedia
The 340B Drug Pricing Program is a US federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices
- 340B Drug Pricing Program | HRSA
Learn about HRSA's Office of Pharmacy Affairs (OPA), ensuring affordable medications through the 340B Drug Pricing Program
- 340B Eligibility | HRSA
Section 340B (a) (4) of the Public Health Service Act lists the covered entities that can participate in the 340B Drug Program Covered entities must recertify their eligibility every year
- Detailed Overview - 340B Health
To understand the 340B drug pricing program (340B program), one must begin in 1990 when Congress created the Medicaid drug rebate program (MDRP) to lower the cost of pharmaceuticals reimbursed by state Medicaid agencies
- Home - 340B Health
340B Health is a nonprofit membership organization of more than 1,600 public and private non-profit hospitals and health systems throughout the U S that participate in the 340B drug pricing program We are the leading advocate and resource for those hospitals who serve their communities through participation in 340B
- 340B Educational Resources | HRSA
Our website provides resources to help 340B Program stakeholders with navigating the 340B Program, including registration and implementation, requirements compliance, program integrity, and more: Listen to our 340B Welcome Webinar for an introduction to the 340B Program
- 340B Report - 340B Report is the indispensable source of independent . . .
In today’s 340B environment, every claim counts With increased oversight, tighter margins, and growing manufacturer restrictions, covered entities need to maximize their 340B savings by capturing every eligible claim One often-overlooked opportunity lies in understanding and monitoring disqualified claims These are
|
|
|